BPC-157: Research Protocol in Tissue Recovery

EXOMA Scientific Team · Publicado el 8 de mayo de 2026 · Actualizado el 24 de agosto de 2026

Review of the pharmacological profile of BPC-157 (Body Protective Compound pentadecapeptide) and the protocols described in preclinical literature for tissue regeneration research.

Chemical identity

BPC-157 (Body Protective Compound-157) is a synthetic 15-amino-acid pentadecapeptide: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

It was originally isolated from human gastric juice by the Sikiric group in the 1990s (University of Zagreb).

Mechanism in preclinical literature

In vitro and animal model studies suggest multiple mechanisms of action:

1. Modulation of the VEGFR2-Akt-eNOS pathway → angiogénesis acelerada
2. Upregulation of growth hormone receptors en fibroblastos tendinosos
3. Modulation of the serotonin-dopamine axis en SNC
4. Inhibition of TNF-α and pro-inflammatory interleukins

Protocols described in the literature

Estos protocolos provienen de literatura preclínica revisada por pares.

Theoretical dose conversion (HED)

The extrapolation of animal to human dose (Human Equivalent Dose) according to FDA guidance is approximately:

• 10 µg/kg in rat ≈ 1.6 µg/kg in human (factor 6.2)
• For a 70 kg subject: ~112 µg as a theoretical reference

This conversion is strictly theoretical and does not imply a recommendation for use.

Standard reconstitution

Vial of 5 mg reconstituted with 2 mL of bacteriostatic water:

• Concentration: 2.5 mg/mL = 250 µg per 0.1 mL = 25 µg per U-100 unit

Vial of 10 mg reconstituted with 2 mL:

• Concentration: 5 mg/mL = 500 µg per 0.1 mL = 50 µg per U-100 unit

Stability

Analytical purity

For any research protocol with BPC-157 to be reproducible, the raw material must meet:

• HPLC purity ≥99%
• Identity confirmed by mass spectrometry
• COA per lot with quantification of impurities
• Endotoxins <1 EU/mg

Investigated synergy

In preclinical literature, BPC-157 has been studied in combination with:

• TB-500 (Thymosin β4): in muscle regeneration models
• GHK-Cu: in dermal wound-healing models

References

1. Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157: vascular recruitment and gastrointestinal tract healing. Curr Pharm Des. 2018;24(18):1990-2001. doi:10.2174/1381612824666180608101119. PMID 29879879. (revisión)
2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010. PMID 21030672. (in vitro/animal)
3. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. doi:10.1002/jor.20096. PMID 16583442. (animal)

Products available at EXOMA

• BPC-157